Journal of the American Society of Nephrology, 05/15/2002, By Robert Short
Hepatitis C virus accounts for the increased rate of diabetes mellitus observed with tacrolimus-treated kidney transplant recipients.
Dr Roy Bloom and colleagues of the Renal-Electrolyte and Hypertension Division, Department of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania undertook a retrospective study of 427 kidney recipients. None had diabetes before transplantation.
The patients were studied to examine the interaction between hepatitis C virus and the use of tacrolimus as maintenance therapy with respect to post-transplant diabetes mellitus (PTDM) by 12 months after transplantation.
PTDM occurred in 39.4 percent of patients positive for hepatitis C virus and just 9.8 percent of hepatitis C negative patients. Multivariate logistic regression showed hepatitis C virus, weight at transplantation, and tacrolimus were associated with PTDM. The adjusted odds ratio for hepatitis C virus was especially high: 5.58; 95 percent CI 2.63-11.83; P=0.0001. Dr Bloom said, “A significant interaction was detected between hepatitis C virus status and tacrolimus use for the odds of PTDM”. He added that among the hepatitis C virus positive patients, PTDM occurred more often in patients treated with tacrolimus (57.8 percent) than with cyclosporine A (7.7 percent). The PTDM rates in hepatitis C negative patients were similar in patients treated with tacrolimus and those treated with cyclosporine A (about 10 percent in both groups.
e-Med Tools
קצר קולע וממוקד
e-Med סמינרים
אי-מד תחקירים
Medscape Tools
Journal Club
מרכזי מידע ושירות
Facebook
מידע למפרסם
מאגר תרופות
מאגר אנשי המקצוע
אינדקס שימושי
חדשות משה"ב
eMed HealthClub
מחקרים קליניים
השאירו תגובה
רוצה להצטרף לדיון?תרגישו חופשי לתרום!